Share this publication:
It was observed that aldosterone blockade in hemodialysis patients represents an important and safe therapeutic strategy owing to the consequent proteinuria and blood pressure reduction. These factors help reduce cardiovascular risk. Moreover, this strategy contributes to decrease renal injury, suggesting a beneficial effect on the prevention of chronic kidney disease.
About the publisher:
iMedPub Limited is a publishing house registered in UK, publishing medical books and journals since 2005. As an open service to doctors and biomedical researchers, it is driven by clinicians and researchers for themselves, while serving the interests of the general public. iMedPub disseminates research in a tiered system, beginning with our specialty books and journals and then working upwards. The grand vision of iMedPub is a world where all medical researchers and health professionals have an equal opportunity to seek, share and create knowledge. As we are a low cost academic publisher we offer the lowest article processing charges of all biomedical journals and publish books free of charges for authors.